Lately, patients with early HER2-positive breast cancer treated with anti-HER2 therapies, lapatinib plus trastuzumab, in the absence of chemotherapy, have shown a correlation between TIL subsets and pCR rate. Here, ERBB2 is linked to breast carcinoma.